D.A. Wallach Explains Why Biotech VC Is So Different

What It Covers

DA Wallach explains why biotech venture capital differs fundamentally from tech investing, with five percent drug success rates, decade-long timelines, clinical trial bottlenecks, and China's emerging competitive advantages in regulatory speed and infrastructure.

Key Questions Answered

• •Success probability management: Biotech drugs have only five percent probability of FDA approval from initial concept, versus ten percent for biologics. Investors must build portfolios managing these low-probability, high-value outcomes where individual wins reach billions but take minimum ten years to materialize.
• •Clinical trial bottleneck: AI can generate more drug candidates, but the industry already drowns in good ideas. The real constraint is testing safety and efficacy on humans, costing thirty to forty million dollars per clinical program with no substitute for human trials currently available.
• •China's structural advantages: Chinese biotech benefits from faster regulatory approvals, lower clinical trial costs, higher volume capacity, and repatriated talent educated in US graduate schools. Recent trials replicated in Europe confirm Chinese data quality, making China the likely dominant force over the next decade.
• •Gray hair premium: Biotech values experienced founders over young talent because clinical programs require thirty to forty million dollar commitments with no easy pivots. Each failure teaches irreplaceable lessons about navigating the translation from academic concepts to marketable products through specialized expertise.